Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | ANPEP | P15144 | 1/20 | 0.49 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7652554 | 0.87 | NPC1 (0.58) | KMT2AMEN1ALDH1A1NPC1RAB9A | |
| SCHEMBL4709745 | 0.86 | PDCD1 (0.52) | KMT2AMEN1ATMCHRM2NPC1 | |
| SCHEMBL21066539 | 0.86 | PDCD1 (0.49) | ATMEPHX2L3MBTL1CA1CA2 | |
| SCHEMBL4913978 | 0.85 | EPHX2 (0.52) | EPHX2NR1H4CA1CA2 | |
| SCHEMBL12310009 | 0.84 | CA1 (0.47) | ATML3MBTL1CA1CA2 | |
| SCHEMBL22452272 | 0.84 | FPR3 (0.47) | ATMNPC1RAB9AL3MBTL1CA1 | |
| SCHEMBL1724201 | 0.84 | GAA (0.60) | KMT2AMEN1CHRM2ALDH1A1KDM4E | |
| SCHEMBL6076877 | 0.84 | HPGD (0.49) | ATMCHRM2ALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL1587057 | 0.84 | GLA (0.50) | KMT2ACHRM2NPC1RAB9AGLA | |
| SCHEMBL22605044 | 0.84 | ATM (0.58) | KMT2AMEN1ATMKDM4ECA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4257192-A2 | ISOQUINOLINE DERIVATIVES AND THEIR USE FOR THE TREATEMTN OF OPHTHALMIC DISORDERS | Industrial Technology Research Institute (TW) | 2023-10-11 | — | — | EP | disclosed |
| EP-3505513-B1 | ISOQUINOLINE DERIVATIVES AND THEIR USE FOR THE TREATEMTN OF OPHTHALMIC DISORDERS | IND TECH RES INST (TW) | 2023-09-27 | — | — | EP | disclosed |
| US-20220324878-A1 | IMIDAZOLIDIN-2-ONE COMPOUNDS AS PRMT5 MODULATORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2022-10-13 | — | — | US | disclosed |
| US-11365205-B2 | Imidazolidin-2-one compounds as PRMT5 modulators | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2022-06-21 | — | — | US | disclosed |
| CN-107304204-B | Method for preparing N-heterocyclic compound | 广东东阳光药业有限公司 | 2020-12-22 | — | — | CN | disclosed |
| US-10696638-B2 | Compounds for inhibiting AGC kinase and pharmaceutical compositions comprising the same | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2020-06-30 | — | — | US | disclosed |
| EP-3505513-A1 | ISOQUINOLINE DERIVATIVES AND THEIR USE FOR THE TREATEMTN OF OPHTHALMIC DISORDERS | Industrial Technology Research Institute (TW) | 2019-07-03 | — | — | EP | disclosed |
| US-20190194137-A1 | COMPOUNDS FOR INHIBITING AGC KINASE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2019-06-27 | — | — | US | disclosed |
| CN-1889836-A | Insecticidal n-(heteroarylalkyl)alkanediamine derivatives | FMC CORP (US) | 2007-01-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11365205-B2 | Imidazolidin-2-one compounds as PRMT5 modulators | PRMT5, PRMT1, PRMT7 | KMT2A 60/4885MEN1 681/4885ATM 537/4885 |
| US-20190194137-A1 | COMPOUNDS FOR INHIBITING AGC KINASE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | GRK4, NCOA4, GRK3 | KMT2A 1680/4885MEN1 4432/4885ATM 778/4885 |
| US-10696638-B2 | Compounds for inhibiting AGC kinase and pharmaceutical compositions comprising the same | GRK4, NCOA4, GRK3 | KMT2A 1680/4885MEN1 4432/4885ATM 778/4885 |
| US-20220324878-A1 | IMIDAZOLIDIN-2-ONE COMPOUNDS AS PRMT5 MODULATORS | PRMT5, PRMT1, PRMT7 | KMT2A 60/4885MEN1 681/4885ATM 537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.